Premiums for Affordable Care Act (Obamacare) plans are increasing again, and these plans come with new rules.
Summary written by Upside AI from the original article. Read the source for full details.
Original headline: Three things that explain what’s changing with Obamacare in 2027
Read the original on MarketWatch ↗
Keywords
Open a keyword to see other news on the same topic.
Related news
- Hartford Insurance Group : 3 Key Takeaways for Long - Term Investors
Hartford Insurance Group reported third-quarter 2026 core earnings of $956 million and a trailing 12-month core return on equity of 17.9%. Management said its automated underwriting processes policies instantly without human review, with 78% of small business submissions bindable straight through. It sees healthcare inflation and expiring federal subsidies pushing up workers' compensation claims, a broad-based trend it says is not unique to its book. The company recently closed its purchase of Equitable's employee benefits division, which brings $500 million in annual premium and expands its dental and vision lines and reach among small and midsized businesses.
- GLP-1 drug coverage is being dropped by employer plans: What to know about 2027 weight-loss options
More employers are dropping coverage of GLP-1 drugs for weight loss or offering smaller payouts, and some are shifting to third-party weight-management programs as healthcare costs climb. A WTW survey found 53% of employers with more than 100 employees cover GLP-1s for weight loss, down from 57% in 2025, while 16% are considering removing coverage, up from 9%. Marsh expects health insurance cost per employee to rise 8.2% in 2027, the biggest increase since 2003, with GLP-1 use accounting for one percentage point of that growth. Some employers direct workers to buy the drugs through NovoCare or LillyDirect, where self-pay Wegovy starts at $149 a month for the pill and $199 for the shot. Gallup reports that 11% of U.S. adults took GLP-1 medications for weight loss in 2026, up from 3% in 2024.
- Centene Corporation Q3 2026 Earnings Call Summary
- Abbott Laboratories vs . UnitedHealth : Does Health Innovation or Health Insurance Make for a Better Stock to Buy ?
The article compares Abbott Laboratories (ABT), a maker of medical devices, diagnostics and nutrition products, with UnitedHealth Group (UNH), which runs the UnitedHealthcare insurance arm and Optum health services. In FY 2025 Abbott's revenue rose about 6% to $44.3 billion, but net income fell to about $6.5 billion from $13.4 billion, largely due to a $385 million settlement. UnitedHealth's revenue grew nearly 12% to about $447.6 billion, while net income dropped to about $12.1 billion from $14.4 billion, a net margin of about 2.7%. Medicaid and Medicare premiums made up 44% of UnitedHealth's 2025 revenue, exposing it to government policy, while Abbott faces FDA oversight and debt from its $20 billion acquisition of Exact Sciences. Free cash flow was about $7.4 billion for Abbott and about $16.1 billion for UnitedHealth in FY 2025.
- Premiums for Employer - Sponsored Family Health Coverage Top $28 , 000 in 2026
According to KFF's annual benchmark survey of large and small employers, workers this year pay an average of $7,471 annually toward employer-sponsored family health premiums, up 9%, or $621, from 2025. Including the employer's share, total annual premiums for family coverage average $28,303, up 5% or $1,310 from 2025. Wages rose 3.7% and general inflation rose 2.7% over the same period, though inflation has been higher in recent months.
- Job - Based Health Plan Costs Rise , With Little Relief in Sight
Rising healthcare costs are hitting employers and workers alike, and more increases are expected for 2027 plans. According to an annual KFF survey released Oct. 22, the amount workers pay toward family coverage rose an average of 9% to $7,471 a year, while the average family premium paid by employers rose 5% to $28,303. Among large employers with at least 200 employees, 44% raised what workers pay toward coverage. Employers also raised deductibles, changed insurers, added preapproval for some services, or narrowed provider networks. Consulting firms Aon and Marsh projected employer costs would rise 9.5% and 8.2% next year, while the Business Group on Health predicted a median premium increase of 9.2%.
Related markets
Latest news
- SpaceX and Tesla face policy and governance risks after Democratic gains
Investing.com reports that the Democratic takeover of Congress is now a direct policy risk for SpaceX (SPCX) and Tesla (TSLA), which fell in the session by about 5% and 5.6% respectively. SpaceX faces pressure from its reliance on government contracts, tighter scrutiny of Starlink's military role, and proposed Texas data-center restrictions that could slow and raise the cost of its AI infrastructure. Morgan Stanley's improved outlook, with its 2027 revenue estimate raised to $175B and its free-cash-flow-positive forecast moved up to 2031, could be offset by a larger political discount. The article calls Tesla more vulnerable, since its valuation depends on autonomy and AI that could face tighter scrutiny, and a SpaceX combination would raise governance concerns, with Barclays estimating Musk could hold about 56% of voting power on roughly 37% of shares.
- Should You Forget VOO and Buy This Magnificent ETF Instead?
The article compares the Roundhill Magnificent Seven ETF (MAGS) with the Vanguard S&P 500 ETF (VOO) as the Nasdaq-100 has fallen about 9% from its early-October high on concerns over AI infrastructure costs. MAGS has averaged 36.9% annual returns since its April 2023 inception through September 30, but only about 12.2% over the past year, mostly due to Apple. The article suggests investors doubtful about AI payoffs may consider VOO instead, noting its portfolio is about 39.7% tech and spread across financials, pharmaceuticals and large-value stocks. It cites Vanguard research suggesting AI's biggest winners could be companies that use AI rather than those building it. VOO has averaged about 12% annually over the past five years, including the 2022 bear market.
- Counterparty Concentration and Depreciation Define CoreWeave Now
CoreWeave (NASDAQ:CRWV) carries a Hold rating at $53.74 after a 40.04% drop over the past month, as investors question who is paying its bills and how quickly its GPUs lose value. The company rents NVIDIA GPU capacity to AI labs, hyperscalers such as Meta, and enterprises, with OpenAI, Meta and Microsoft as its largest counterparties. Second-quarter revenue reached $2.58 billion, up 112.3% year over year, and the revenue backlog stands at $104.2 billion. Depreciation and amortization hit $1.393 billion, about 54% of revenue, while interest expense rose to $640 million from $267 million. Total liabilities of $72.05 billion sit against $5.02 billion of equity, and the average analyst target of $134.58 comes from 42 analysts.
- Oracle Continues to Crash Lower and Lower But Two Bullish Desks Agree That Its Price WIll More Than Triple
Oracle (NYSE:ORCL) trades at $126.21, well below the $234.10 average analyst target, and two desks, Guggenheim and Mizuho, carry $400 targets. The stock is down 34.39% year to date, while its remaining performance obligations (RPO) stand at $664B, up $209B year over year. Oracle launched a new $20 billion offering of common stock and senior notes, following a $20B at-the-market equity program. In the first quarter, capex reached $28.5B, free cash flow was negative $5.4B, and interest expense rose 55% to $1.4B. The article says the bullish case depends on the backlog converting to revenue on schedule, while total liabilities of $236B remain a risk to watch.
- ELEKTROS Highlights Northern New York Lithium Potential Amid Growing Focus on Domestic Battery Supply
ELEKTROS Inc. (OTC PINK:ELEK) is conducting an initial, exploratory assessment of a possible hard-rock lithium property in northern New York close to the Canadian border, but has not acquired the property and no independently verified mineral resource or reserve exists. The company is also exploring development relationships tied to its multi-port EV charging patent, U.S. Patent No. 12,522,100 B1, though no prototype, patent license, customer deployment or revenue has been announced. The article cites remarks by Elon Musk and President Donald J. Trump on lithium-ion batteries and critical minerals in general, which do not refer to the company. A Benchmark Mineral Intelligence outlook cited by Benzinga suggests global lithium demand could more than triple by 2050, but this is an industry projection, not a company forecast.
- Forget the 12-Month Squeeze: Microsoft Is Primed for an Explosive AI Payoff
Microsoft (NASDAQ:MSFT) shares rose just 1.6% over the past year, while net income grew 32.01% in the latest quarter, a gap the author argues most investors are misreading. The author sees Microsoft earning revenue at every layer of corporate AI use, from Azure capacity to Foundry and Copilot. In the quarter ended Sept 30, 2026, revenue reached $92.28B, up 18.8%, Microsoft Cloud brought in $63.9B, up 30%, and Azure grew 48%. Commercial remaining performance obligations reached $677B, up 73%, and non-GAAP EPS came in at $4.89 against a $4.72 estimate. The article also flags spending risk, with cash capex of $39.37B last quarter, up 102.99%, and fiscal 2026 free cash flow down 6.46% to $66.99B.
Get the briefing on Telegram or Zalo
Join the Upside Telegram channel or Zalo group for the Vietnam stocks and gold briefing at 8:00 and 19:00 (Vietnam time) on trading days, plus a weekly wrap on Saturday morning.